User Tools

Site Tools


In 1990, Macdonald et al.defined the criteria for evaluating response to treatment and disease progression. They suggested that variations in the tumor-enhancing area, neurological function, and steroid dosage should be considered in the assessment of tumor response 1). Although these criteria have since been the cornerstone in response evaluation in many phase II clinical trials, some doubts have been expressed regarding the evaluation of disease progression in patients treated with TMZ concomitant with radiotherapy.

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990 Jul;8(7):1277-80. PubMed PMID: 2358840.
1990.txt · Last modified: 2018/10/14 12:52 by administrador